Association of Circulating Tumor Cells with Serum Tumor-Related Methylated DNA in Peripheral Blood of Melanoma Patients

Por Koyanagi, Kazuo, Mori, Takuji, O’Day, Steven J., Martinez, Steve R., Wang, He-Jing, Hoon, Dave S.B.
Publicado em 2006

Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy

Por Shinozaki, Masaru, O’Day, Steven J., Kitago, Minoru, Amersi, Farin, Kuo, Christine, Kim, Joseph, Wang, He-Jing, Hoon, Dave S.B.
Publicado em 2007

Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma

Por Taback, Bret, O’Day, Steven J., Boasberg, Peter D., Shu, Sherry, Fournier, Patricia, Elashoff, Robert, Wang, He-Jing, Hoon, Dave S. B.
Publicado em 2004

mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen–Specific Monoclonal Antibody B...

Por Kitago, Minoru, Koyanagi, Kazuo, Nakamura, Takeshi, Goto, Yasufumi, Faries, Mark, O’Day, Steven J., Morton, Donald L., Ferrone, Soldano, Hoon, Dave S.B.
Publicado em 2009

Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients

Por Koyanagi, Kazuo, Kuo, Christine, Nakagawa, Taku, Mori, Takuji, Ueno, Hideaki, Lorico, Arnulfo R., Wang, He-Jing, Hseuh, Eddie, O’Day, Steven J., Hoon, Dave S.B.
Publicado em 2005

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Por Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., Wolchok, J. D.
Publicado no Ann Oncol (2014)

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Por Anthony Stephen P, Stephenson Joe, Senzer Neil N, Cunningham C Casey, Eager Robert M, O'Day Steven J, Frenette Gary, Pavlick Anna C, Jones Barry, Uprichard Margaret, Nemunaitis John
Publicado em 2009-07-01

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Por Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John
Publicado em 2009

Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients

Por Koyanagi, Kazuo, O’Day, Steven J., Gonzalez, Rene, Lewis, Karl, Robinson, William A., Amatruda, Thomas T., Kuo, Christine, Wang, He-Jing, Milford, Robert, Morton, Donald L., Hoon, Dave S.B.
Publicado em 2006

Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial

Por Koyanagi, Kazuo, O’Day, Steven J., Gonzalez, Rene, Lewis, Karl, Robinson, William A., Amatruda, Thomas T., Wang, He-Jing, Elashoff, Robert M., Takeuchi, Hiroya, Umetani, Naoyuki, Hoon, Dave S.B.
Publicado em 2005

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

Por Wolchok, Jedd D., Weber, Jeffrey S., Hamid, Omid, Lebbé, Celeste, Maio, Michele, Schadendorf, Dirk, de Pril, Veerle, Heller, Kevin, Chen, Tai-Tsang, Ibrahim, Ramy, Hoos, Axel, O'Day, Steven J.
Publicado em 2010

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Por Amin, Asim, Lawson, David H., Salama, April K.S., Koon, Henry B., Guthrie, Troy, Thomas, Sajeve S., O’Day, Steven J., Shaheen, Montaser F., Zhang, Bin, Francis, Stephen, Hodi, F. Stephen
Publicado no J Immunother Cancer (2016)

Estrogen Receptor-α Methylation Predicts Melanoma Progression

Por Mori, Takuji, Martinez, Steve R., O’Day, Steven J., Morton, Donald L., Umetani, Naoyuki, Kitago, Minoru, Tanemura, Atsushi, Nguyen, Sandy L., Tran, Andy N., Wang, He-Jing, Hoon, Dave S.B.
Publicado em 2006

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Por Wolchok, Jedd D, Hodi, F Stephen, Weber, Jeffrey S, Allison, James P, Urba, Walter J, Robert, Caroline, O'Day, Steven J, Hoos, Axel, Humphrey, Rachel, Berman, David M, Lonberg, Nils, Korman, Alan J
Publicado em 2013

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

Por Leung, Anna M., Lee, Agnes Fermin, Ozao-Choy, Junko, Ramos, Romela Irene, Hamid, Omid, O’Day, Steven J., Shin-Sim, Myung, Morton, Donald L., Faries, Mark B., Sieling, Peter A., Lee, Delphine J.
Publicado em 2014

Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy

Por Mori, Takuji, O’Day, Steven J., Umetani, Naoyuki, Martinez, Steve R., Kitago, Minoru, Koyanagi, Kazuo, Kuo, Christine, Takeshima, Teh-Ling, Milford, Robert, Wang, He-Jing, Vu, Vu D., Nguyen, Sandy L., Hoon, Dave S.B.
Publicado em 2005

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Por Koyanagi, Kazuo, O’Day, Steven J., Boasberg, Peter, Atkins, Michael B., Wang, He-Jing, Gonzalez, Rene, Lewis, Karl, Thompson, John A., Anderson, Clay M., Lutzky, Jose, Amatruda, Thomas T., Hersh, Evan, Richards, Jon, Weber, Jeffrey S., Hoon, Dave S. B.
Publicado em 2010

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

Por Kim, Kevin B., Sosman, Jeffrey A., Fruehauf, John P., Linette, Gerald P., Markovic, Svetomir N., McDermott, David F., Weber, Jeffrey S., Nguyen, Hoa, Cheverton, Peter, Chen, Daniel, Peterson, Amy C., Carson, William E., O'Day, Steven J.
Publicado no J Clin Oncol (2012)

Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes

Por Morton, Donald L., Hsueh, Eddy C., Essner, Richard, Foshag, Leland J., O’Day, Steven J., Bilchik, Anton, Gupta, Rishab K., Hoon, Dave S. B., Ravindranath, Mepur, Nizze, J. Anne, Gammon, Guy, Wanek, Leslie A., Wang, He-jing, Elashoff, Robert M.
Publicado em 2002

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

Por Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Publicado em 2012